Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU in danger of double standards as generics association calls for IP work-around

This article was originally published in Scrip

Executive Summary

The European Generic medicines Association (EGA) wants the EU to allow Europe-based manufacturers to get around existing rules that prevent them exporting biosimilars to countries where the originator molecule is not patented protected. But some companies in India have said that if the EU were to introduce such a provision, its posture in the ongoing EU-India free trade agreement negotiations would make it guilty of double standards.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts